Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Condition(s) studied
Investigational drug(s) / intervention(s)
Efanesoctocog alfa: Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous
Study summary
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A.
The study duration for each participant is approximately 12 months.
Eligibility
Primary outcome measure(s)
- Proportion of joints with improvement in the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovitis domain score — From Baseline up to Week 52
HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.
Trial sites (19)
| Facility | City | Region | Status |
|---|---|---|---|
| Orthopedic Institute for Children- Site Number : 8400009 | Los Angeles | California | Completed |
| University of California Davis Medical Center-Site Number: 8400005 | Sacramento | California | Recruiting |
| Indiana Hemophilia and Thrombosis Center- Site Number : 8400006 | Indianapolis | Indiana | Recruiting |
| University of Iowa- Site Number : 8400004 | Iowa City | Iowa | Recruiting |
| The Ohio State University Wexner Medical Center - CarePoint East- Site Number : 8400001 | Columbus | Ohio | Completed |
| Oregon Health and Science University-Site Number: 8400002 | Portland | Oregon | Recruiting |
| Washington Center for Bleeding Disorders- Site Number : 8400008 | Seattle | Washington | Recruiting |
| Investigational Site Number : 0360001 | Murdoch | Western Australia | Completed |
| Investigational Site Number : 1240002 | Calgary | Alberta | Recruiting |
| Investigational Site Number : 1240001 | St. John's | Newfoundland and Labrador | Recruiting |
| Investigational Site Number : 1240003 | Hamilton | Ontario | Recruiting |
| Investigational Site Number : 1240004 | Hamilton | Ontario | Completed |
| Investigational Site Number : 3920003 | Kawasaki | Kanagawa | Recruiting |
| Investigational Site Number : 3920002 | Hiroshima | Japan | Completed |
| Investigational Site Number : 3920001 | Saitama | Japan | Recruiting |
| Investigational Site Number : 3920004 | Tokyo | Japan | Completed |
| Investigational Site Number: 1580003 | Kaohsiung City | Taiwan | Recruiting |
| Investigational Site Number: 1580001 | Taichung | Taiwan | Recruiting |
| Investigational Site Number: 1580002 | Taipei | Taiwan | Recruiting |
More Sanofi trials in Australia
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06941870 on ClinicalTrials.gov ↗ ← All trials in Australia